Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Research & Development: 2018-2025

Historic Research & Development for Whitehawk Therapeutics (WHWK) over the last 7 years, with Sep 2025 value amounting to $14.3 million.

  • Whitehawk Therapeutics' Research & Development rose 43.49% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.3 million, marking a year-over-year increase of 74.49%. This contributed to the annual value of $51.0 million for FY2024, which is 4.29% up from last year.
  • According to the latest figures from Q3 2025, Whitehawk Therapeutics' Research & Development is $14.3 million, which was down 70.61% from $48.8 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Research & Development peaked at $48.8 million during Q2 2025, and registered a low of $3.0 million during Q2 2021.
  • Moreover, its 3-year median value for Research & Development was $13.1 million (2024), whereas its average is $15.6 million.
  • The largest annual percentage gain for Whitehawk Therapeutics' Research & Development in the last 5 years was 272.79% (2025), contrasted with its biggest fall of 35.35% (2025).
  • Over the past 5 years, Whitehawk Therapeutics' Research & Development (Quarterly) stood at $7.2 million in 2021, then climbed by 29.65% to $9.4 million in 2022, then spiked by 36.26% to $12.8 million in 2023, then grew by 12.37% to $14.3 million in 2024, then soared by 43.49% to $14.3 million in 2025.
  • Its Research & Development was $14.3 million in Q3 2025, compared to $48.8 million in Q2 2025 and $8.8 million in Q1 2025.